@article {Broncel:September 2008:1871-5230:206,
	author = "Broncel, Marlena",
	author = "Kozirog, Marzena",
	author = "Chojnowska-Jezierska, Julita",
	title = "Lipid Lowering Agents, Inflammation and Atherosclerosis",
	journal = "Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Cu rrent Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents)",
	volume = "7",
	year = "September 2008",
	abstract = "Atherosclerosis has been recognized as an inflammatory disease. The innate and adaptive immunity mechanisms are involved in atherogenesis. Low-grade inflammation is associated with innate immunity activation. The CRP has been proposed as the best indicator of low-grade inflammation and a predictor of cardiovascular events. A triumvirate of targets in the prevention of CVD are: LDL-C aggressive lowering, HDL-C increasing and CRP lowering. The statins&#39; role in lipids and CRP lowering is well established. Moreover, statins may be beneficial in many other inflammatory immune conditions. Among PPAR-&#945; agonists, anti-inflammatory properties of fenofibrate are the best demonstrated. PPAR-&#947; agonists (thiazolidinediones) pleiotropic effects are also promising. PPAR &#945;/&#947; agonists have been proved to cause severe side effects. Ezetimibe exerts beneficial anti-inflammatory actions when administered with statins. Colesevelam, a novel bileacid sequestrant has beneficial lipid-lowering and anti-inflammatory actions. CETP and ACAT inhibitors actions call for further studies. Inhibition of CRP, CRP-targeted antisenses, HDL-particle modification and immunomodulation of atherosclerosis are possible novel approaches in atherosclerosis treatment and prevention. <P></P> <P></P> <P></P>",
	pages = "206-216(11)",
	url = "http://www.ingentaconnect.com/content/ben/aiaamc/2008/00000007/00000003/art00008"
	doi = "doi:10.2174/187152308785699254"
}